Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality at a discount Quality Strong, Valuation Undervalued, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is primarily a manufacturer of generic drugs, covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.The company operates in multiple international markets including the United States, Japan, Europe, and Australia..
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #10 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 9 Sep 2021 | Dr. Kamal K Sharma | Employee / designated person | Sell | 0 | ₹0 |
| 6 Sep 2021 | MR. NILESH D. GUPTA | Promoter | Sell | 0 | ₹0 |
| 6 Sep 2021 | Veda Nilesh Gupta | Promoter | Buy | 0 | ₹0 |
| 6 Sep 2021 | MR. NEEL DESHBANDHU GUPTA | Promoter | Buy | 0 | ₹0 |
| 27 Aug 2021 | MR. NILESH D. GUPTA | Promoter | Buy | 0 | ₹0 |
| 18 Aug 2021 | SUNIL MAKHARIA | Employee / designated person | Sell | 0 | ₹0 |
| 16 Aug 2021 | Ramesh Swaminathan | Employee / designated person | Sell | 0 | ₹0 |
| 10 Jul 2021 | MR. NILESH D. GUPTA | Promoter | Sell | 0 | ₹0 |
| 10 Jul 2021 | Veda Nilesh Gupta | Promoter | Buy | 0 | ₹0 |
| 30 Jun 2021 | SUNIL MAKHARIA | Employee / designated person | Sell | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 14 Oct 2025 | GOLDMAN SACHS BANK EUROPE SE - ODI | Block | Buy | 60,035 | 1937.5000 | NSE |
| 14 Oct 2025 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | Block | Sell | 60,035 | 1937.5000 | NSE |
| 13 Oct 2025 | GOLDMAN SACHS BANK EUROPE SE - ODI | Block | Buy | 81,892 | 1977.0000 | NSE |
| 13 Oct 2025 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | Block | Sell | 81,892 | 1977.0000 | NSE |
| 14 Jul 2025 | STATE STREET MSCI ACWI EX USA IMI SCREENED NON-LENDING COMMON TRUST FUND | Block | Buy | 52,861 | 1894.7000 | BSE |
| 14 Jul 2025 | STATE STREET MSCI ACWI EX USA IMI SCREENED NON-LENDING COMMON TRUST FUND | Block | Sell | 52,861 | 1894.7000 | BSE |
| 25 Jan 2024 | SOCIETE GENERALE | Block | Buy | 747,956 | 1449.2000 | BSE |
| 25 Jan 2024 | BNP PARIBAS ARBITRAGE | Block | Sell | 747,956 | 1449.2000 | BSE |
| 25 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | Block | Sell | 213,033 | 680.7500 | BSE |
| 25 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | Block | Buy | 213,033 | 680.7500 | BSE |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| — | NAME_CHANGE | Name changed from Lupin Chemicals Ltd to Lupin Ltd |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 6 Aug 2026 | Financial Results/Other business matters | Yes |
| 7 May 2026 | Financial Results/Dividend/Other business matters | Yes |
| 12 Feb 2026 | Financial Results/Other business matters | Yes |
| 6 Nov 2025 | Financial Results/Other business matters | Yes |
| 5 Aug 2025 | Financial Results/Other business matters | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 1 Oct 2026 | Company Update | Lupin Ltd - 500257 - Completion Of Buyback Of Shares By Multicare Pharmaceuticals Philippines, Inc. |
| 28 Sep 2026 | Insider Trading / SAST | Lupin Ltd - 500257 - Closure of Trading Window |
| 28 Sep 2026 | Company Update | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release |
| 21 Sep 2026 | Company Update | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS |
| 8 Sep 2026 | Company Update | Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.
Part of: NIFTY 200, NIFTY 200, NIFTY 500, NIFTY 500, NIFTY MIDCAP 100, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY MIDCAP 150, NIFTY MIDCAP 50, NIFTY MIDCAP 50, NIFTY PHARMA, NIFTY PHARMA
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
